Orgenesis Insiders
ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Orgenesis employs about 146 people. The company is managed by 12 executives with a total tenure of roughly 341 years, averaging almost 28.0 years of service per executive, having 12.17 employees per reported executive. Breaking down Orgenesis' management performance can provide insight into the firm performance.
Victor Miller Executive Chief Officer |
Osher Rheinisch Executive General Officer |
Orgenesis |
Orgenesis Management Team Effectiveness
The company has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2725) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.Orgenesis Workforce Comparison
Orgenesis is regarded third in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,144. Orgenesis retains roughly 146 in number of employees claiming about 13% of equities under Health Care industry.
Orgenesis Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orgenesis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orgenesis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Orgenesis insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Safier Jacob over two months ago Acquisition by Safier Jacob of 3000 shares of Orgenesis at 0.5421 subject to Rule 16b-3 | ||
Safier Jacob over two months ago Acquisition by Safier Jacob of 100000 shares of Orgenesis at 0.6895 subject to Rule 16b-3 | ||
Safier Jacob over three months ago Acquisition by Safier Jacob of 603 shares of Orgenesis at 0.8608 subject to Rule 16b-3 | ||
Philips Mario over three months ago Acquisition by Philips Mario of 6250 shares of Orgenesis at 4.7 subject to Rule 16b-3 | ||
Yachin Guy over three months ago Acquisition by Yachin Guy of 19600 shares of Orgenesis at 2.89 subject to Rule 16b-3 | ||
Adler Yaron over three months ago Acquisition by Adler Yaron of 12500 shares of Orgenesis at 2.99 subject to Rule 16b-3 | ||
Nanda Ashish over three months ago Acquisition by Nanda Ashish of 189320 shares of Orgenesis at 1.03 subject to Rule 16b-3 | ||
Adler Yaron over three months ago Acquisition by Adler Yaron of 37662 shares of Orgenesis subject to Rule 16b-3 |
Orgenesis Notable Stakeholders
An Orgenesis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Orgenesis often face trade-offs trying to please all of them. Orgenesis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Orgenesis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph Carpinelli | Chief Octomera | Profile | |
Victor Miller | Chief Officer | Profile | |
Osher Rheinisch | General Officer | Profile | |
Neil CPA | S CFO | Profile | |
Shimon Hassin | Chief Officer | Profile | |
Efrat Kunik | Chief Officer | Profile | |
Pierre Lammeretz | Interim Officer | Profile | |
Evan Fishman | Chief Officer | Profile | |
Dan Slonim | COO Israel | Profile | |
Vered MSc | CEO Board | Profile | |
Pr Ferber | Founder Officer | Profile | |
Vincent Vandamme | VP Strategy | Profile |
About Orgenesis Management Performance
The success or failure of an entity such as Orgenesis often depends on how effective the management is. Orgenesis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Orgenesis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Orgenesis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.
The data published in Orgenesis' official financial statements typically reflect Orgenesis' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Orgenesis' quantitative information. For example, before you start analyzing numbers published by Orgenesis accountants, it's essential to understand Orgenesis' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Orgenesis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Orgenesis. Check Orgenesis' Beneish M Score to see the likelihood of Orgenesis' management manipulating its earnings.
Orgenesis Workforce Analysis
Traditionally, organizations such as Orgenesis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Orgenesis within its industry.Orgenesis Manpower Efficiency
Return on Orgenesis Manpower
Revenue Per Employee | 3.6K | |
Revenue Per Executive | 44.2K | |
Net Loss Per Employee | 444.6K | |
Net Loss Per Executive | 5.4M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |